<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e>) evolve through multiple pathways </plain></SENT>
<SENT sid="1" pm="."><plain>These pathways may be defined based on two molecular features: (1) <z:mp ids='MP_0008866'>chromosomal instability</z:mp> and (2) chromosomal stability </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumors</z:e> showing chromosomal stability evolve through the so-called microsatellite instability pathway </plain></SENT>
<SENT sid="3" pm="."><plain>These types of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> show different clinico-pathological features and need different therapy so very important to separate them </plain></SENT>
<SENT sid="4" pm="."><plain>As <z:chebi fb="1" ids="51686">Hematoxylin</z:chebi>-Eosin (HE) based histology is influenced by the different genetic alterations of a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>, it is reasonable that different gene expression profiles result in different HE <z:mp ids='MP_0000002'>morphology</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Our aim was to find specific histomorphological features specific for <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> showing different molecular features </plain></SENT>
<SENT sid="6" pm="."><plain>We analyzed the clinicopathological parameters of 324 colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp>, 26 hereditary non-<z:e sem="disease" ids="C0334108" disease_type="Neoplastic Process" abbrv="">polyposis</z:e> <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e>, 32 <z:hpo ids='HP_0003745'>sporadic</z:hpo> high-level microsatellite-instable (MSI-H) <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and 266 microsatellite-stable or low-level microsatellite-instable (MSI-L) <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> among them </plain></SENT>
<SENT sid="7" pm="."><plain>Our results showed that we could recognize different genetic types of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> on the base of clinicopathological features like patient's age, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> localization and histological characteristics of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Main histological parameters help in differentiation are inflammatory background, nuclear features and pattern of infiltration </plain></SENT>
<SENT sid="9" pm="."><plain>Clinical parameters like clinical stage and localization and careful histological analysis helps to select molecular method to define molecular features and to select the most appropriate therapy of a given <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
</text></document>